To confirm that the antitumor immune response in OSU13- and anti–PD-1–treated mice was CD8 T cell–dependent, as we previously observed with OSU13 alone (Figure 5H), we compared MC38 tumor inhibition in CD8+ T cell–depleted and nondepleted mice. The gene discussed is CD8A; the disease is neoplasm.